Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Chimeric Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Australian biotech figurehead Paul Hopper raises $20 million for his latest pre-IPO venture
Health & Biotech
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
Health & Biotech
Dr Boreham’s Crucible: Who’s winning and losing in the life sciences IPO Olympiad?
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
Health & Biotech
ASX Health Stocks: Chimeric gets licence for CAR-T from U-Pen, Acrux gets nod from the FDA
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
IPO Watch
IPO Watch: Which sector has provided the best performing IPOs in 2021?
Health & Biotech
‘Miracle’ breakthrough in melanoma fight puts focus on ASX stocks in the skin cancer space
Health & Biotech
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention
Health & Biotech
Invion led a group of ASX cancer stocks up after promising news
Health & Biotech
Anteotech flags in-house scale up for its COVID-19 test kit, shares edge higher
Stockhead TV
V-Con: IPOs roaring into 2021
Health & Biotech
Awareness of the Pfizer vaccine in Australia could unlock a new health investment trend, says one VC
Health & Biotech
Chimeric achieves milestone on Phase I cell therapy for glioblastoma cancer
IPO Watch
IPO Watch: Mosquito disease fighter Island Pharmaceuticals doubles on debut
IPO Watch
Uranium explorer 92 Energy eyes ASX listing for mid-April
Experts